Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot open study of testosterone replacement in non-alcoholic steatohepatitis
2012-002564-27Phase 2Completed
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Jan 2013
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of testosterone undecanoate in metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD) and Hypoandrogenism (TD), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Improvement in severity of steatosis. Started Jan 2013; status: completed.
02
Drugs
testosterone undecanoate
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)Hypoandrogenism (TD)
Beyond the preview
Go deeper on 2012-002564-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002564-27.